Sylvestin
43-amino-acid contact-kinin pathway inhibitor from forest leech Haemadipsa sylvestris — plasma kallikrein + FXIIa dual blocker; preclinical stroke neuroprotection without bleeding tendency.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- 43-amino-acid contact-kinin pathway inhibitor from forest leech Haemadipsa sylvestris — plasma kallikrein + FXIIa dual blocker; preclinical stroke neuroprotection without bleeding tendency.
- Evidence level
- Preclinical (animal)
- Drug vs leech
- Recombinant (genetically expressed)
- Safety domains
- Bleeding
Clinical translation limit
Sylvestin's neuroprotection in rodent ischemic stroke models does NOT establish clinical efficacy in humans. No FDA-approved sylvestin derivative exists. The reported 'no bleeding tendency' result is from animal models only; human bleeding-risk profiles cannot be inferred.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 4,790 Da
- Source species
- Haemadipsa sylvestris
- Discovered
- 2022 · Zhang Z et al.
Biological Targets
- → plasma kallikrein
- → activated Factor XII (FXIIa)
Key Citations
- Zhang Z et al. (2022), Cell Mol Life Sci · PMID 35416530
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.